Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.64 (
proteinase K
)
4,071
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BHK cells transfected with human lysosomal acid phosphatase (LAP) cDNA (
CT29
) expressed 70-fold higher enzyme activities of acid phosphatase than non-transfected BHK cells. The
CT29
-LAP was synthesized in BHK cells as a heterogeneously glycosylated precursor that was tightly membrane associated. Transfer to the trans-Golgi was associated with a small increase in size (approximately 7 kd) and partial processing of the oligosaccharides to complex type structures.
CT29
-LAP was transferred into lysosomes as shown by subcellular fractionation, immunofluorescence and immunoelectron microscopy. Lack of mannose-6-phosphate residues suggested that transport does not involve mannose-6-phosphate receptors. Part of the membrane-associated
CT29
-LAP was processed to a soluble form. The mechanism that converts
CT29
-LAP into a soluble form was sensitive to NH4Cl, and reduced the size of the polypeptide by 7 kd. In vitro translation of
CT29
-derived cRNA in the presence of microsomal membranes yielded a
CT29
-LAP precursor that is protected from
proteinase K
except for a small peptide of approximately 2 kd. In combination with the sequence data available for LAP, these observations suggest that
CT29
-LAP is synthesized and transported to lysosomes as a transmembrane protein. In the lysosomes,
CT29
-LAP is released from the membrane by proteolytic cleavage, which removes a C-terminal peptide including the transmembrane domain and the cytosolic tail of 18 amino acids.
...
PMID:Human lysosomal acid phosphatase is transported as a transmembrane protein to lysosomes in transfected baby hamster kidney cells. 305 14